Renub

    Spinal Muscular Atrophy Market, Global Forecast by Countries, Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) & Companies

    Excel: 4 Hours
    PDF: 4 Hours
    Nov 2018
    Pages: 121

    Get Free Customization in This Report

    Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally.  Spinal muscular atrophy is basically 4 types Type 1, Type 2, Type 3 and Type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.     


    Request a free sample copy of the report: https://www.renub.com/contactus.php 


    Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months.  In spinal muscular atrophy type 2, patients can sit but cannot walk.  Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood. 

     

    Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.


    Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years

    At present only Biogen’s Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc.  Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.  


    By Country - Market Segmentation

    Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.


    By Total & Treated Patients - Population Segmentation

    Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally. 


    By Drugs - Market Segmentation

    The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.

    spinal-muscular-atrophy-market-global-by-countries-drugs-companies-and-forecast

    The Report has been analyzed from 9 Major Viewpoints

    1.   Global Spinal Muscular Atrophy Market (Present & Forecast)
    2.   Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)
    3.    Country Spinal Muscular Atrophy Market (Present & Forecast)
    4.    Country Spinal Muscular Atrophy Patients Population (Present & Forecast)
    5.    Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)
    6.    Spinal Muscular Atrophy Drugs Sales (Present & Forecast)
    7.    Global – Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline 
    8.    Growth Drivers and Challenges
    9.    Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight

     

    Client can purchase this report in sections through Purchase by Chapter Tab given above


    Country Covered in this Report

    •    United States
    •    United Kingdom
    •    France 
    •    Germany
    •    Italy 
    •    Spain
    •    Japan


    Drugs Details Covered in this Report

    •    Spinraza
    •    AVXS-101
    •    CK2127107
    •    RG7916
    •    Olesoxime
    •    LMI070


    Company Covered in this Report

    •    Biogen Inc.
    •    Roche AG
    •    Novartis AG
    •    Cytokinetics Inc

     

    If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com

    1.    Introduction

    1.1    Market Definition
    1.2    Currency Conversion

    2.    Research Methodology

    3.    Executive Summary

    4.    Global Spinal Muscular Atrophy Market and Patients Analysis

    4.1    Spinal Muscular Atrophy Market
    4.2    Spinal Muscular Atrophy Patient Numbers
    4.3    Spinal Muscular Atrophy Treated Patient Number

    5.    Share Analysis – Global Spinal Muscular Atrophy

    5.1    Country Market Share
    5.2    Patients Population Share
    5.3    Treated Patients Share

    6.    United States

    6.1    Spinal Muscular Atrophy Market
    6.2    Spinal Muscular Atrophy Patient Numbers
    6.3    Spinal Muscular Atrophy Treated Patients

    7.    United Kingdom

    7.1    Spinal Muscular Atrophy Market
    7.2    Spinal Muscular Atrophy Patient Numbers
    7.3    Spinal Muscular Atrophy Treated Patient Numbers

    8.    Germany

    8.1    Spinal Muscular Atrophy Market
    8.2    Spinal Muscular Atrophy Patient Numbers
    8.3    Spinal Muscular Atrophy Treated Patients

    9.    Italy – Spinal Muscular Atrophy

    9.1    Spinal Muscular Atrophy Market
    9.2    Spinal Muscular Atrophy Patient Numbers
    9.3    Spinal Muscular Atrophy Treated Patient Numbers

    10.    France – Spinal Muscular Atrophy

    10.1    Spinal Muscular Atrophy Market
    10.2    Spinal Muscular Atrophy Patient Numbers
    10.3    Spinal Muscular Atrophy Treated Patient Numbers

    11.    Spain

    11.1    Spinal Muscular Atrophy Market
    11.2    Spinal Muscular Atrophy Patient Numbers
    11.3    Spinal Muscular Atrophy Treated Patient Numbers

    12.    Japan

    12.1    Spinal Muscular Atrophy Market
    12.2    Spinal Muscular Atrophy Patients
    12.3    Spinal Muscular Atrophy Treated Patient Numbers

    13.    Drugs Sales – Spinal Muscular Atrophy

    13.1    Spinraza
    13.2    AVXS-101
    13.3    CK2127107
    13.4    RG7916
    13.5    Olesoxime
    13.6    LMI070

    14.    Spinal Muscular Atrophy Study Status Analysis

    14.1    Spinal Muscular Atrophy Clinical Study
    14.2    Spinal Muscular Atrophy Drugs Development Pipeline

    15.    Growth Drivers

    15.1    Increasing Funding for Research & Development
    15.2    Biogen Access Programs

    16.    Challenges

    16.1    High Treatment Cost
    16.2    Common Side Effects

    17.    Biogen Inc.

    17.1    Business Overview
    17.2    Initiatives/Strategies

    17.2.1    Point 1
    17.2.2    Point 2
    17.2.3    Point 3

    17.3    Financial Insight

    18.    Novartis AG

    18.1    Business Overview
    18.2    Initiatives/Strategies

    18.2.1    Point 1
    18.2.2    Point 2

    18.3    Financial Insight

    19.    Roche Holding AG

    19.1    Business Overview
    19.2    Initiatives/Strategies

    19.2.1    Point 1
    19.2.2    Point 2

    19.3    Financial Insight

    20.    Cytokinetics, Inc.

    20.1    Business Overview
    20.2    Initiatives/Strategies

    20.2.1    Point 1
    20.2.2    Point 2

    20.3    Financial Insight

     


    List of Figures:

    Figure 4‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 4‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 4‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 5‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 – 2026
    Figure 5‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026
    Figure 5‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 – 2026

    Figure 6‑1: United States – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 6‑2: United States – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 6‑3: United States – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 7‑1: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 7‑2: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 7‑3: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 8‑1: Germany – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 8‑2: Germany – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 8‑3: Germany – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 9‑1: Italy – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 9‑2: Italy – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 9‑3: Italy – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 10‑1: France – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 10‑2: France – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 10‑3: France – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 11‑1: Spain – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 11‑2: Spain – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 11‑3: Spain – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 12‑1: Japan – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
    Figure 12‑2: Japan – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
    Figure 12‑3: Japan – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

    Figure 13‑1: Global – Current & Forecast for Spinraza Sales (Million US$), 2017 – 2026
    Figure 13‑2: Global – Current & Forecast for AVXS-101 Sales (Million US$), 2017 – 2026
    Figure 13‑3: Global – Current & Forecast for CK212710 Sales (Million US$), 2022 – 2026
    Figure 13‑4: Global – Current & Forecast for RG7916 Sales (Million US$), 2024 – 2026
    Figure 13‑5: Global – Current & Forecast for LMI070 Sales (Million US$), 2021 – 2026

    Figure 14‑1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018

    Figure 17‑1: Biogen – Global Sales (Million US$), 2013 – 2017
    Figure 17‑2: Biogen – Forecast for Global Sales (Million US$), 2018 – 2026

    Figure 18‑1: Novartis – Global Sales (Million US$), 2013 – 2017
    Figure 18‑2: Novartis – Forecast for Global Sales (Million US$), 2018 – 2026

    Figure 19‑1: Roche – Global Sales (Million US$), 2013 – 2017
    Figure 19‑2: Roche – Forecast for Global Sales (Million US$), 2018 – 2026

    Figure 20‑1: Cytokinetics – Global Sales (Thousand US$), 2013 – 2017
    Figure 20‑2: Cytokinetics – Forecast for Global Sales (Million US$), 2018 – 2026

     

    List of Tables:

    Table 14-1: Global – Spinal Muscular Atrophy Clinical Study Status, 2018

    • Description
      Price
    • Chapter 1, 2, 3 & 4     Pages : 8
      $800
    • Chapter 5     Pages : 3
      $700
    • Chapter 6     Pages : 3
      $500
    • Chapter 7     Pages : 4
      $500
    • Chapter 8     Pages : 3
      $500
    • Chapter 9     Pages : 3
      $500
    • Chapter 10     Pages : 4
      $500
    • Chapter 11     Pages : 3
      $500
    • Chapter 12     Pages : 3
      $500
    • Chapter 13     Pages : 9
      $600
    • Chapter 14     Pages : 43
      $300
    • Chapter 15     Pages : 2
      $250
    • Chapter 16     Pages : 3
      $250
    • Chapter 17     Pages : 5
      $250
    • Chapter 18     Pages : 5
      $250
    • Chapter 19     Pages : 6
      $250
    • Chapter 20     Pages : 4
      $250

    Related Reports